Nebibio

Composition: 

Each uncoated tablet contains:

Nebivolol Hydrochloride equivalent to Nebivolol 5 mg

Description:

Nebivolol is a ß-adrenergic receptor blocking agent. It is a racemate of enantiomers L-nebivolol and d-nebivolol.  Nebivolol is a long acting cardioselective beta blocker licensed for treatment of hypertension. It has vasodilatory property attributed to interaction with L-arginine/nitric oxide pathway. It thus enhances endothelial nitric oxide release.

Indications:

• Hypertension
• Stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients ≥ 70 years

 Dosage and administration:

Hypertension

In hypertension the usual initial dose of Nebivolol is 5 mg once daily. Dosage reduction may be necessary in the elderly and in patients with hepatic or renal impairment.

Chronic heart failure in elderly

In heart failure the initial dose of Nebivolol is 1.25 mg once daily. If tolerated, the dose should be doubled every 1 to 2 weeks up to a maximum of 10 mg once daily.

Contraindications:

•Severe bradycardia

•Heart block greater than first degree

•Cardiogenic shock

•Decompensated cardiac failure

•Sick sinus syndrome (unless a permanent pacemaker is in place)

•Hypertensives with severe hepatic impairment (Child-Pugh >B)

•Heart failure patients with hepatic impairment

•Heart failure patients with severe renal insufficiency (serum creatinine  250μmol/L)

•Hypersensitivity to any component of this product

Presentation:

Alu-Alu Blister of 10 tablets.